Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
WiSe 2025
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
-
WiSe 2024
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome : a case for universal genetic testing?In: ESMO Gastrointestinal Oncology, Jg. 9, 2025, 100218DOI (Open Access)
-
90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous TumorsIn: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 9, S. 1378 – 1384
-
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer : Lessons from the PREDICT trialIn: Molecular Cancer, Jg. 24, 2025, Nr. 1, 202DOI (Open Access)
-
Body Composition in Cholangiocarcinoma Affects Immune Cell Populations in the Tumor and Normal Liver ParenchymaIn: Journal of Clinical and Experimental Hepatology, Jg. 15, 2025, Nr. 2, 102460DOI (Open Access)
-
Correction to : Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine‑induced hypo‑vascularizationIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 52, 2025, Nr. 10, S. 3916 – 3917DOI (Open Access)
-
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligenceIn: Nature Cancer, Jg. 6, 2025, Nr. 2, S. 307 – 322DOI (Open Access)
-
Degradable Starch Microsphere Transarterial Chemoembolization as Salvage Therapy in Patients with Uveal Melanoma Liver MetastasesIn: Journal of Vascular and Interventional Radiology (JVIR), Jg. 36, 2025, Nr. 9, S. 1418 – 1426.e1DOI (Open Access)
-
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistanceIn: Signal Transduction and Targeted Therapy, Jg. 10, 2025, Nr. 1, 319DOI (Open Access)
-
Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?In: Radiology and Oncology, Jg. 59, 2025, Nr. 3, S. 383 – 390DOI, Online Volltext (Open Access)
-
Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinomaIn: Nature Cancer, Jg. 6, 2025, Nr. 5, S. 820 – 837DOI (Open Access)
-
Fibroblast-directed PET imaging reveals a case of retroperitoneal fibrosis after immunotherapy for metastatic urothelial cancer of the upper tractIn: Urology Case Reports, Jg. 61, 2025, 103105DOI (Open Access)
-
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage responseIn: Molecular Systems Biology, Jg. 21, 2025, Nr. 3, S. 231 – 253DOI (Open Access)
-
Gut microbiota deficiency reduces neutrophil activation and is protective after ischemic strokeIn: Journal of Neuroinflammation, Jg. 22, 2025, Nr. 1, 137DOI (Open Access)
-
Head-to-head comparison of ⁶⁸ Ga-FAPI-46 PET/CT, ¹⁸F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumorsIn: Annals of Nuclear Medicine, Jg. 39, 2025, Nr. 3, S. 255 – 265
-
How Rapidly Does the FAPI PET Signal Reverse Following Therapy? : Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in MiceIn: Journal of Nuclear Medicine (JNM), Jg. 66, 2025, Nr. 11, S. 1757 – 1763DOI (Open Access)
-
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratificationIn: npj Digital Medicine, Jg. 8, 2025, Nr. 1, 611DOI (Open Access)
-
METAPANC – intensivierte Behandlung bei Patient*innen mit lokal operablem, aber oligometastasiertem Pankreaskarzinom : Multimodale chirurgische Therapie versus alleinige Chemotherapie – eine randomisierte, kontrollierte Phase-III-Studie (AIO-PAK-0219, IAG-VO-0822)In: Die Onkologie, Jg. 31, 2025, Nr. 10, S. 1015 – 1019
-
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNAIn: Molecular Oncology, Jg. 19, 2025, Nr. 2, S. 357 – 376DOI, Online Volltext (Open Access)
-
PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinomaIn: Cell Reports, Jg. 44, 2025, Nr. 4, 115541DOI (Open Access)
-
Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone : A randomized controlled trialIn: BMC Cancer, Jg. 25, 2025, Nr. 1, 208DOI (Open Access)
-
The Prognostic Value of the XPC rs2228001 Single Nucleotide Polymorphism in CholangiocarcinomaIn: Liver International, Jg. 45, 2025, Nr. 9, e70292DOI (Open Access)
-
Transcription factor switching drives subtype-specific pancreatic cancerIn: Nature Genetics, Jg. 57, 2025, Nr. 12, S. 3016 – 3026DOI (Open Access)
-
[⁶⁸Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation : A single-centre, single-arm, interventional, phase 2 trialIn: The Lancet Oncology, Jg. 26, 2025, Nr. 9, S. 1204 – 1214DOI (Open Access)
-
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 6, S. 880 – 887
-
Are histomorphological patterns a predictor for survival in uveal melanoma patients with hepatic metastases undergoing hepatic artery infusion chemotherapy?In: Journal of Medical Imaging and Radiation Oncology, Jg. 68, 2024, Nr. 7, S. 862 – 869DOI (Open Access)
-
Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatmentIn: Nature Communications, Jg. 15, 2024, Nr. 1, 4120DOI (Open Access)
-
CellViT : Vision Transformers for precise cell segmentation and classificationIn: Medical Image Analysis, Jg. 94, 2024, 103143DOI (Open Access)
-
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy : a pooled analysis of five clinical trials from two decades of the German AIO study groupIn: ESMO Open, Jg. 9, 2024, Nr. 4, 102944DOI (Open Access)
-
Corrigendum to “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: (NEOLAP-AIO-PAK-0113)” : results from a prospective, multicenter phase II trialIn: ESMO Open, Jg. 9, 2024, Nr. 5, 103463DOI (Open Access)
-
Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided OptimizationIn: ACS Chemical Biology, Jg. 19, 2024, Nr. 2, S. 266 – 279DOI, Online Volltext (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-FAPI Versus ¹⁸F-FDG PET in Patients with Various MalignanciesIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 3, S. 372 – 378DOI (Open Access)
-
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancerIn: Nature Communications, Jg. 15, 2024, Nr. 1, 10534DOI (Open Access)
-
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 2, S. 252 – 257DOI (Open Access)
-
Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma : A Prospective, Single-Center, Observational TrialIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 8, S. 1188 – 1193
-
Histology-Based Radiomics for [¹⁸F]FDG PET Identifies Tissue Heterogeneity in Pancreatic CancerIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 7, S. 1151 – 1159DOI (Open Access)
-
Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009–2021In: Cancer Epidemiology, Jg. 93, 2024, 102659DOI (Open Access)
-
Liver volumetry improves evaluation of treatment response to hepatic artery infusion chemotherapy in uveal melanoma patients with liver metastasesIn: Radiology and Oncology, Jg. 58, 2024, Nr. 4, S. 509 – 516DOI, Online Volltext (Open Access)
-
P-move : A randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapyIn: Supportive Care in Cancer, Jg. 32, 2024, Nr. 7, 437DOI (Open Access)
-
Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylationIn: Clinical Epigenetics, Jg. 16, 2024, Nr. 1, 13DOI, Online Volltext (Open Access)
-
Prognostic Implications of ⁶⁸Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid TumorsIn: Journal of Nuclear Medicine (JNM), Jg. 65, 2024, Nr. 7, S. 1027 – 1034
-
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer : A retrospective multicenter studyIn: ESMO Open, Jg. 9, 2024, Nr. 1, 102219DOI, Online Volltext (Open Access)
-
Stroke and myocardial infarction induce neutrophil extracellular trap release disrupting lymphoid organ structure and immunoglobulin secretionIn: Nature Cardiovascular Research, Jg. 3, 2024, Nr. 5, S. 525 – 540DOI (Open Access)
-
Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survivalIn: Theranostics, Jg. 14, 2024, Nr. 14, S. 5400 – 5412DOI, Online Volltext (Open Access)
-
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer : Is it really a valid tool for patient selection?In: Clinical and Translational Oncology, Jg. 26, 2024, Nr. 5, S. 1268 – 1272DOI (Open Access)
-
Understanding homologous recombination repair deficiency in biliary tract cancers : clinical implications and correlation with platinum sensitivityIn: ESMO Open, Jg. 9, 2024, Nr. 8, 103630DOI (Open Access)
-
[⁶⁸Ga]Ga-FAPI versus 2-[¹⁸F]FDG PET/CT in patients with autoimmune thyroiditis : A case control studyIn: EJNMMI Research, Jg. 14, 2024, Nr. 1, 66DOI, Online Volltext (Open Access)
-
68Ga-Labeled Fibroblast Activation Protein Inhibitor (⁶⁸Ga-FAPI) PET for Pancreatic Adenocarcinoma : Data from the ⁶⁸Ga-FAPI PET Observational TrialIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 12, S. 1910 – 1917DOI (Open Access)
-
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)In: Oncology Research and Treatment, Jg. 46, 2023, Nr. 3, S. 89 – 99
-
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaIn: Clinical Cancer Research, Jg. 29, 2023, Nr. 2, S. 488 – 500DOI (Open Access)
-
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinomaIn: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 8, S. 5085 – 5094DOI (Open Access)
-
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer : MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformIn: The Oncologist, Jg. 28, 2023, Nr. 6, S. 553 - 554, e455 - e472DOI (Open Access)
-
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy ProtocolsIn: Oncology Research and Treatment, Jg. 46, 2023, Nr. 4, S. 140 – 150
-
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcriptionIn: Science Advances, Jg. 9, 2023, Nr. 41, eadg5109DOI (Open Access)
-
Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cellsIn: British Journal of Haematology, Jg. 202, 2023, Nr. 5, S. 1033 – 1048DOI (Open Access)
-
Fibroblast Activation Protein Inhibitor Theranostics : The Case for Use in SarcomaIn: PET Clinics, Jg. 18, 2023, Nr. 3, S. 361 – 367
-
Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal AdenocarcinomaIn: Molecular Pharmaceutics, Jg. 20, 2023, Nr. 8, S. 4319 – 4330DOI (Open Access)
-
Fibroblast Activation Protein-Targeting Minibody-IRDye700DX for Ablation of the Cancer-Associated Fibroblast with Photodynamic TherapyIn: Cells, Jg. 12, 2023, Nr. 10, 1420DOI (Open Access)
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 5, S. 711 – 716DOI (Open Access)
-
Histology-Based Prediction of Therapy Response to Neoadjuvant Chemotherapy for Esophageal and Esophagogastric Junction Adenocarcinomas Using Deep LearningIn: JCO Clinical Cancer Informatics (JCO CCI), Jg. 7, 2023, e2300038DOI (Open Access)
-
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 8, S. 4315 – 4325DOI (Open Access)
-
Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal AdenocarcinomaIn: Molecular Cancer Research, Jg. 21, 2023, Nr. 9, S. 881 – 891DOI (Open Access)
-
Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh®TM) Methodology : A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic CancerIn: Current Oncology, Jg. 30, 2023, Nr. 6, S. 5828 – 5834DOI (Open Access)
-
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancerIn: Gut, Jg. 72, 2023, Nr. 6, S. 1174 – 1185DOI, Online Volltext (Open Access)
-
LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer GrowthIn: Clinical Cancer Research, Jg. 29, 2023, Nr. 6, S. 1137 – 1154
-
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancerIn: Nature, Jg. 615, 2023, Nr. 7950, S. 168 – 174DOI (Open Access)
-
Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotypeIn: Gut, Jg. 72, 2023, Nr. 3, S. 522 – 534DOI (Open Access)
-
Novel ⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine-Related PitfallsIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 3, S. 368 – 371DOI (Open Access)
-
Oncologic Staging with ⁶⁸Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than ¹⁸F-FDG PET/CTIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 12, S. 1906 – 1909DOI (Open Access)
-
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafuspIn: European Journal of Cancer (EJC), Jg. 191, 2023, 112986DOI (Open Access)
-
Precision neuro-oncology : A pilot analysis of personalized treatment in recurrent gliomaIn: Journal of Cancer Research and Clinical Oncology, Jg. 149, 2023, Nr. 7, S. 3513 – 3526DOI (Open Access)
-
Protocol of the IntenSify-Trial : An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacyIn: Clinical and Translational Science (CTS), Jg. 16, 2023, Nr. 12, S. 2483 – 2493DOI (Open Access)
-
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axisIn: Molecular Cancer, Jg. 22, 2023, Nr. 1, 52DOI, Online Volltext (Open Access)
-
Smaller panel, similar results : Genomic profiling and molecularly informed therapy in pancreatic cancerIn: ESMO Open, Jg. 8, 2023, Nr. 3, 101539DOI (Open Access)
-
Superior Tumor Detection for ⁶⁸Ga-FAPI-46 Versus ¹⁸F-FDG PET/CT and Conventional CT in Patients with CholangiocarcinomaIn: Journal of Nuclear Medicine (JNM), Jg. 64, 2023, Nr. 7, S. 1049 – 1055DOI (Open Access)
-
Tebentafusp in Patients with Metastatic Uveal Melanoma : A Real-Life Retrospective Multicenter StudyIn: Cancers, Jg. 15, 2023, Nr. 13, 3430DOI (Open Access)
-
Bcl-x(L) as prognostic marker and potential therapeutic target in cholangiocarcinomaIn: Liver International, Jg. 42, 2022, Nr. 12, S. 2855 – 2870DOI (Open Access)
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine, Jg. 12, 2022, Nr. 11, e1090DOI, Online Volltext (Open Access)
-
Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancerIn: Translational Oncology, Jg. 15, 2022, Nr. 1, 101279DOI (Open Access)
-
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersIn: Annals of Oncology, Jg. 33, 2022, Nr. 11, S. 1186 – 1199DOI (Open Access)
-
Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients with Resectable or Borderline Resectable Disease (COMM-PACT-RB) : A Systematic Review and Delphi Consensus StatementIn: JAMA Oncology, Jg. 8, 2022, Nr. 6, S. 929 – 937DOI, Online Volltext (Open Access)
-
Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group Molecular Diagnostics and Therapy”In: European Journal of Cancer (EJC), Jg. 162, 2022, S. 245 – 246
-
Das Pankreaskarzinom : Klinische Projekte der onkologischen Studiengruppen in Deutschland (ACO, AIO und ARO)In: Der Onkologe, Jg. 28, 2022, Nr. Suppl. 1, S. 30 – 35
-
Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.In: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 50, 2022, Nr. 1, S. 115 – 129DOI (Open Access)
-
Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinomaIn: Cancer & Metabolism, Jg. 10, 2022, Nr. 1, 24DOI (Open Access)
-
Gene expression-based prediction of pazopanib efficacy in sarcomaIn: European Journal of Cancer (EJC), Jg. 172, 2022, S. 107 – 118
-
Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 PatientsIn: Journal of Nuclear Medicine (JNM), Jg. 63, 2022, Nr. 5, S. 727 – 734DOI (Open Access)
-
MCL1 as putative target in pancreatoblastomaIn: Virchows Archiv, Jg. 481, 2022, Nr. 2, S. 265 – 272DOI (Open Access)
-
Multimodal survival prediction in advanced pancreatic cancer using machine learningIn: ESMO Open, Jg. 7, 2022, Nr. 5, 100555DOI, Online Volltext (Open Access)
-
PET-directed combined modality therapy for gastroesophageal junction cancer : Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK)In: European Journal of Cancer (EJC), Jg. 175, 2022, S. 99 – 106
-
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer : A randomized phase-II study - The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510In: International Journal of Cancer, Jg. 150, 2022, Nr. 6, S. 1007 – 1017DOI (Open Access)
-
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancerIn: OncoImmunology, Jg. 11, 2022, Nr. 1, 2043037DOI (Open Access)
-
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases : translational results from the German multicenter AIO-YMO-PAK-0515 studyIn: ESMO Open, Jg. 7, 2022, Nr. 1, 100388DOI (Open Access)
-
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy : results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)In: ESMO Open, Jg. 7, 2022, Nr. 4, 100552DOI (Open Access)
-
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expressionIn: Nature Communications, Jg. 13, 2022, Nr. 1, 156DOI (Open Access)
-
Radiation Dose Aspects of Hepatic Artery Infusion Chemotherapy in Uveal Melanoma Patients with Liver MetastasesIn: Cardiovascular and Interventional Radiology, Jg. 45, 2022, Nr. 6, S. 841 – 845DOI (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research, Jg. 28, 2022, Nr. 19, S. 4346 – 4353DOI (Open Access)
-
The clinical utility of cfRNA for disease detection and surveillance : A proof of concept study in non-small cell lung cancerIn: Thoracic Cancer, Jg. 13, 2022, Nr. 15, S. 2180 – 2191DOI, Online Volltext (Open Access)
-
⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomasIn: Scientific Reports, Jg. 12, 2022, Nr. 1, 16261DOI, Online Volltext (Open Access)
-
A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosisIn: iScience, Jg. 24, 2021, Nr. 3, 102173DOI (Open Access)
-
Antitumor immune response is associated with favorable survival in GEP-NEN G3In: Endocrine-Related Cancer, Jg. 28, 2021, Nr. 10, S. 683 – 693
-
Author Correction: Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCCIn: Scientific Reports, Jg. 11, 2021, Nr. 1, 11705DOI (Open Access)
-
Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodelingIn: Journal of Nuclear Cardiology, Jg. 28, 2021, Nr. 3, S. 812 – 821DOI (Open Access)
-
Cellular model system to dissect the isoform-selectivity of Akt inhibitorsIn: Nature Communications, Jg. 12, 2021, Nr. 1, 5297DOI (Open Access)
-
Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology, Jg. 147, 2021, Nr. 2, S. 579 – 591DOI (Open Access)
-
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersIn: Cancer Discovery, Jg. 11, 2021, Nr. 11, S. 2780 – 2795DOI (Open Access)
-
Duktales Adenokarzinom des Pankreas : Entstehung, Diagnostik, TherapieIn: Der Gastroenterologe, Jg. 16, 2021, Nr. 1, S. 41 – 50
-
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC) : A post hoc analysis of NAPOLI-1In: Pancreatology, Jg. 21, 2021, Nr. 1, S. 192 – 199DOI (Open Access)
-
Ecg scoring for the evaluation of therapy-naïve cancer patients to predict cardiotoxicityIn: Cancers, Jg. 13, 2021, Nr. 6, 1197DOI, Online Volltext (Open Access)
-
Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCCIn: Scientific Reports, Jg. 11, 2021, Nr. 1, 1191DOI (Open Access)
-
Laktatdehydrogenase vor transarterieller hepatischer Chemoperfusion prognostiziert das Überleben und den Tumorprogress bei Patienten mit Lebermetastasen bei AderhautmelanomIn: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, Jg. 193, 2021, Nr. 06, S. 683 – 691DOI (Open Access)
-
Localized Angiosarcoma, Not One Disease : A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and EtiologyIn: Sarcoma, Jg. 2021, 2021, 9960085DOI (Open Access)
-
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IIn: Nature Communications, Jg. 12, 2021, Nr. 1, 5505DOI (Open Access)
-
Monosomy 3 is linked to resistance to mek inhibitors in uveal melanomaIn: International Journal of Molecular Sciences (IJMS), Jg. 22, 2021, Nr. 13, 6727DOI (Open Access)
-
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113) : a multicentre, randomised, phase 2 trialIn: The Lancet Gastroenterology & Hepatology, Jg. 6, 2021, Nr. 2, S. 128 – 138
-
Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinomaIn: EJNMMI Research, Jg. 11, 2021, Nr. 1, 120DOI, Online Volltext (Open Access)
-
Poly(ADP-ribose) polymerase inhibition in pancreatic cancerIn: Genes, Chromosomes and Cancer, Jg. 60, 2021, Nr. 5, S. 373 – 384DOI (Open Access)
-
Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusionIn: Radiology and Oncology, Jg. 55, 2021, Nr. 3, S. 347 – 353DOI, Online Volltext (Open Access)
-
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer modelsIn: Genome Medicine, Jg. 13, 2021, Nr. 1, 116DOI (Open Access)
-
Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasisIn: Cell Reports, Jg. 37, 2021, Nr. 8, 110056DOI, Online Volltext (Open Access)
-
The Latest Developments in Imaging of Fibroblast Activation ProteinIn: Journal of Nuclear Medicine (JNM), Jg. 62, 2021, Nr. 2, S. 160 – 167DOI (Open Access)
-
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastomaIn: Cell Death and Disease, Jg. 12, 2021, Nr. 10, 885DOI (Open Access)
-
The predictive and prognostic significance of cell-free DNA concentration in melanomaIn: Journal of the European Academy of Dermatology and Venereology, Jg. 35, 2021, Nr. 2, S. 387 – 395DOI (Open Access)
-
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progressionIn: Nature Communications, Jg. 12, 2021, Nr. 1, 3895DOI (Open Access)
-
[¹⁸F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinomaIn: EJNMMI Research, Jg. 11, 2021, Nr. 1, 70DOI (Open Access)
-
Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemiaIn: Therapeutic Advances in Hematology, Jg. 11, 2020, 2040620720933761DOI, Online Volltext (Open Access)
-
Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinomaIn: International Journal of Cancer, Jg. 147, 2020, Nr. 10, S. 2847 – 2861DOI (Open Access)
-
Conceptual framework for precision cancer medicine in Germany : Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’In: European Journal of Cancer (EJC), Jg. 135, 2020, S. 1 – 7
-
Duktales Adenokarzinom des Pankreas : Entstehung, Diagnostik, TherapieIn: Der Onkologe, Jg. 26, 2020, Nr. 10, S. 977 – 985
-
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerIn: Cell Death and Disease, Jg. 11, 2020, Nr. 10, 875DOI (Open Access)
-
Image-Based Molecular Phenotyping of Pancreatic Ductal AdenocarcinomaIn: Journal of Clinical Medicine (JCM), Jg. 9, 2020, Nr. 3, 724DOI (Open Access)
-
Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncologyIn: JCI Insight, Jg. 5, 2020, Nr. 15, e137809DOI (Open Access)
-
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer : Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 TrialIn: Pancreas, Jg. 49, 2020, Nr. 1, S. 62 – 75DOI (Open Access)
-
Loss of Wasl improves pancreatic cancer outcomeIn: JCI Insight, Jg. 5, 2020, Nr. 10, e127275DOI (Open Access)
-
Mir34a constrains pancreatic carcinogenesisIn: Scientific Reports, Jg. 10, 2020, Nr. 1, 9654DOI (Open Access)
-
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastomaIn: Scientific Reports, Jg. 10, 2020, Nr. 1, 7157DOI, Online Volltext (Open Access)
-
Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic : Are There Any Concerns?In: Journal of Nuclear Medicine (JNM), Jg. 61, 2020, Nr. 8, S. 1094 – 1095DOI (Open Access)
-
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)In: International Journal of Cancer, Jg. 147, 2020, Nr. 9, S. 2493 – 2502DOI (Open Access)
-
Plasma next generation sequencing and droplet digital-qpcr-based quantification of circulating cell-free rna for noninvasive early detection of cancerIn: Cancers, Jg. 12, 2020, Nr. 2, 353DOI, Online Volltext (Open Access)
-
Proton Irradiation Increases the Necessity for Homologous Recombination Repair Along with the Indispensability of Non-Homologous End JoiningIn: Cells, Jg. 9, 2020, Nr. 4, 889DOI, Online Volltext (Open Access)
-
Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 TrialIn: Clinical Chemistry, Jg. 66, 2020, Nr. 12, S. 1510 – 1520DOI (Open Access)
-
TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancerIn: Cell Death Discovery, Jg. 6, 2020, Nr. 1, 12DOI (Open Access)
-
The transcription factor FLI1 promotes cancer progression by affecting cell cycle regulationIn: International Journal of Cancer, Jg. 147, 2020, Nr. 1, S. 189 – 201DOI (Open Access)
-
Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinomaIn: Oncogene, Jg. 39, 2020, Nr. 24, S. 4770 – 4779DOI (Open Access)
-
A Novel Approach for Image-Guided I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene DeliveryIn: Molecular Cancer Research, Jg. 17, 2019, Nr. 1, S. 310 – 320DOI (Open Access)
-
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapyIn: PLoS ONE, Jg. 14, 2019, Nr. 10, e0218642DOI (Open Access)
-
A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imagingIn: European Radiology Experimental, Jg. 3, 2019, Nr. 1, 41DOI (Open Access)
-
Covalent-Allosteric Inhibitors to Achieve Akt Isoform-SelectivityIn: Angewandte Chemie International Edition, Jg. 58, 2019, Nr. 52, S. 18823 – 18829DOI (Open Access)
-
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer : a subgroup analysis of the pivotal NAPOLI-1 trialIn: Journal of Geriatric Oncology, Jg. 10, 2019, Nr. 3, S. 427 – 435DOI (Open Access)
-
MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In VivoIn: Stem Cells International, Jg. 2019, 2019, 8475389DOI (Open Access)
-
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer : Final overall survival analysis and characteristics of long-term survivorsIn: European Journal of Cancer (EJC), Jg. 108, 2019, S. 78 – 87DOI (Open Access)
-
Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers : pooled data from three independent cohortsIn: Clinical and Translational Oncology, Jg. 21, 2019, Nr. 8, S. 1108 – 1111
-
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic CancerIn: Cancers, Jg. 11, 2019, Nr. 8, 1068DOI (Open Access)
-
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal CancerIn: Cancer Research, Jg. 79, 2019, Nr. 9, S. 2367 – 2378
-
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorinIn: European Journal of Cancer (EJC), Jg. 106, 2019, S. 24 – 33DOI (Open Access)
-
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma CellsIn: Journal of Investigative Dermatology, Jg. 139, 2019, Nr. 12, S. 2506 – 2516.e10DOI (Open Access)
-
18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancerIn: OncoTarget, Jg. 9, 2018, Nr. 11, S. 10128 – 10134DOI (Open Access)
-
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseIn: The Lancet Oncology, Jg. 19, 2018, Nr. 3, S. e151 – e160DOI, Online Volltext (Open Access)
-
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX : A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’In: European Journal of Cancer (EJC), Jg. 94, 2018, S. 95 – 103
-
Epigenetics of gastrointestinal diseases : notes from a workshopIn: Epigenetics, Jg. 13, 2018, Nr. 4, S. 449 – 457DOI (Open Access)
-
Fibroblast-activating protein : Targeting the roots of the tumor microenvironmentIn: Journal of Nuclear Medicine (JNM), Jg. 59, 2018, Nr. 9, S. 1412 – 1414DOI (Open Access)
-
Immunotherapy and Combination Strategies in Pancreatic Cancer : Current Status and Emerging TrendsIn: Oncology Research and Treatment, Jg. 41, 2018, Nr. 5, S. 286 – 290
-
Notch-induced myeloid reprogramming in spontaneous pancreatic ductal adenocarcinoma by dual genetic targetingIn: Cancer Research, Jg. 78, 2018, Nr. 17, S. 4997 – 5010DOI (Open Access)
-
PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSIIn: Biochimica et Biophysica Acta (BBA) - General Subjects, Jg. 1862, 2018, Nr. 1, S. 51 – 60DOI, Online Volltext (Open Access)
-
PICCA study : panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer ; a randomised biomarker-driven clinical phase II AIO studyIn: European Journal of Cancer (EJC), Jg. 92, 2018, S. 11 – 19
-
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1 : Expanded analysis of a global phase 3 trialIn: European Journal of Cancer (EJC), Jg. 105, 2018, S. 71 – 78DOI (Open Access)
-
Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinomaIn: Scientific Reports, Jg. 7, 2017, 17038DOI (Open Access)
-
Co-clinical assessment of tumor cellularity in pancreatic cancerIn: Clinical Cancer Research, Jg. 23, 2017, Nr. 6, S. 1461 – 1470
-
Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic PlasticityIn: Gastroenterology, Jg. 152, 2017, Nr. 6, S. 1507 – 1520.e15DOI (Open Access)
-
Epigenetic treatment of pancreatic cancer : Is there a therapeutic perspective on the horizon?In: Gut, Jg. 66, 2017, Nr. 1, S. 168 – 179DOI (Open Access)
-
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancerIn: British Journal of Cancer (BJC), Jg. 116, 2017, Nr. 11, S. 1462 – 1469DOI (Open Access)
-
Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4-and MYC-dependent mannerIn: Nucleic Acids Research, Jg. 45, 2017, Nr. 11, S. 6334 – 6349DOI (Open Access)
-
Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) geneIn: OncoTarget, Jg. 8, 2017, Nr. 20, S. 33393 – 33404DOI (Open Access)
-
Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung CancerIn: Neoplasia: An International Journal for Oncology Research, Jg. 19, 2017, Nr. 1, S. 8 – 16DOI, Online Volltext (Open Access)
-
Knockdown of myeloid cell hypoxia-inducible factor-1α ameliorates the acute pathology in DSS-induced colitisIn: PLoS ONE, Jg. 12, 2017, Nr. 12, e0190074DOI (Open Access)
-
Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic LesionsIn: eBioMedicine, Jg. 15, 2017, S. 90 – 99DOI, Online Volltext (Open Access)
-
Quality-adjusted survival with combination nal-IRIFU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy : a Q-TWiST analysisIn: British Journal of Cancer (BJC), Jg. 116, 2017, Nr. 10, S. 1247 – 1253DOI (Open Access)
-
Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse ModelIn: The American Journal of Pathology, Jg. 186, 2016, Nr. 11, S. 2934 – 2944
-
Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cellsIn: Oncogene, Jg. 35, 2016, Nr. 29, S. 3880 – 3886DOI, Online Volltext (Open Access)
-
Membranous CD24 drives the epithelial phenotype of pancreatic cancerIn: OncoTarget, Jg. 7, 2016, Nr. 31, S. 49156 – 49168DOI (Open Access)
-
Modeling therapy response and spatial tissue distribution of erlotinib in pancreatic cancerIn: Molecular Cancer Therapeutics, Jg. 15, 2016, Nr. 5, S. 1145 – 1152DOI (Open Access)
-
Next-generation metabolic imaging in pancreatic cancerIn: Gut, Jg. 65, 2016, Nr. 3, S. 367 – 369
-
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyIn: Journal of Hepatology, Jg. 65, 2016, Nr. 2, S. 280 – 288
-
γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targetsIn: OncoTarget, Jg. 7, 2016, Nr. 39, S. 62799 – 62813DOI (Open Access)
-
PERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer : a translational subgroup analysis from AIO-PK0104In: BMC Cancer, Jg. 14, 2014, Nr. 1, 624DOI (Open Access)
-
Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104)
2013 Gastrointestinal Cancers Symposium, January 24-26, 2013, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. 4 Suppl., S. 189 -
S3-Leitlinie zum exokrinen PankreaskarzinomIn: Zeitschrift für Gastroenterologie, Jg. 51, 2013, Nr. 12, S. 1395 – 1440
-
EGF Receptor Is Required for KRAS-Induced Pancreatic TumorigenesisIn: Cancer Cell, Jg. 22, 2012, Nr. 3, S. 304 – 317DOI (Open Access)
-
MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancerIn: PLoS ONE, Jg. 7, 2012, Nr. 6, e39424DOI (Open Access)
-
An inducible Tet-Off-H2B-GFP lentiviral reporter vector for detection and in vivo isolation of label-retaining cellsIn: Experimental Cell Research, Jg. 316, 2010, Nr. 11, S. 1885 – 1895
-
Identification of epidermal pdx1 expression discloses different roles of notch1 and notch2 in murine krasG¹²D-induced skin carcinogenesis in vivoIn: PLoS ONE, Jg. 5, 2010, Nr. 10, e13578DOI (Open Access)
-
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinomaIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS), Jg. 107, 2010, Nr. 30, S. 13438 – 13443DOI (Open Access)
-
Pancreatic cancer transcriptomes : molecular stratification in the adjuvant settingIn: Annals of Oncology. Amsterdam: Elsevier, Jg. 32, 2021, Nr. 2, S. 133 – 135DOI (Open Access)
-
68Ga-FAPI-46 PET for Imaging of FAP-expressing Cancer : Results from a Prospective, Single-Arm, Interventional Phase 2 Clinical TrialIn: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 66, 2025, Nr. Supplement 1, 251524Online Volltext (Open Access)
-
Role of pelareorep in activating anti-tumor immunity in PDACIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. Suppl. 16, S. 2562 – 2562DOI (Open Access)
-
UNITEPANC: Using organoids to predict efficacy of adjuvant treatment to improve outcome in resectable pancreatic cancer : Prospective, multicenter, proof-of-concept trial of the AIO Pancreatic Cancer GroupIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. Suppl. 4, TPS791DOI (Open Access)
-
Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer : The COMBATBIL imCORE trial
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S229 -
Evolutionary and immune microenvironment dynamics determine response to neoadjuvant treatment of oesophageal adenocarcinoma
ESMO Gastrointestinal Cancers Congress 2024, 26-29 June 2024, Munich, Germany,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Supplement 1, S. S168 – S169 -
Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)
ESMO Gastrointestinal Cancers Congress 2024, 26-29 June 2024, Munich, Germany,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Supplement 1, S. S155 -
Homologous recombination repair (HRR) deficiency in biliary tract cancers : Clinical implications in subsequent therapy lines and correlation with platinum sensitivity
ESMO Gastrointestinal Cancers Congress 2024, 26-29 June 2024, Munich, Germany,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Supplement 1, S. S127 -
METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer : Multimodal surgical treatment versus systemic chemotherapy alone: A prospective randomized controlled multicenter phase III trial
2024 ASCO Annual Meeting, 31 May - 04 June 2024, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 42, 2024, Nr. Suppl. 16, TPS4207 -
Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma : Results from the SEPION/AIO-PAK-0118 phase I/II study
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S931 -
Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2, S. S294 -
Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer : The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 35, 2024, Nr. Suppl. 2: Abstract Book of the ESMO Congress 2024, 13-17 September 2024, S. S1218 -
68Ga-FAPI-46 PET for imaging of FAP expressing cancer - interim findings from a single-center prospective interventional single-arm clinical trial
55th Annual Conference of the Society of Nuclear Medicine (SNMICON), November 16-19, 2023, Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P706 -
Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy : A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group
ESMO 25th World Congress on Gastrointestinal Cancer 2023, 28 June - 1 July 2023, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 1: Abstract Book of the ESMO 25th World Congress on Gastrointestinal Cancer 2023, Barcelona, Spain, 28 June - 1 July 2023, S. S164DOI (Open Access) -
Fibroblast activation protein alpha (FAPα) directed imaging and radioligand therapy in patients with solitary fibrous tumor (SFT)
55th Annual Conference of the Society of Nuclear Medicine (SNMICON), November 16-19, 2023, Jodhpur, India,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 64, 2023, Nr. Suppl. 1, P714 -
Head-to-head comparison of68Ga-FAPI46 PET/CT,18F-FDG PET/CT, and contrast- enhanced CT in patient with various solid tumors
Annual Congress of the European Association of Nuclear Medicine, 9-13 September, 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S166 – S167 -
Molecular characterization of biliary tract cancer at a single comprehensive cancer center focusing on DNA damage repair genes
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 46, 2023, Nr. Supplement 5: DGHO Abstracts, S. 62DOI (Open Access) -
Occurence of hematotoxic side effects during 90Y-FAPI-46 radioligand therapy (RLT) in patients with advanced metastatic tumor diseases
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S671DOI (Open Access) -
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG). Hoboken: Wiley-Blackwell - STM, Jg. 20, 2022, Nr. S3, S. 12 – 13 -
P-5 Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 +/- spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)
ESMO 24th World Congress on Gastrointestinal Cancer 2022, 29 June -2 July 2022, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Suppl. 4, S. S247DOI (Open Access) -
Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO): SEP 09-13, 2022; Paris, France,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Suppl. 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S762 – S763DOI (Open Access) -
Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1231 – S1232DOI (Open Access) -
Selective elimination of CD133+ cancer stem cells using novel BET/HDAC inhibitor TW09 as therapy for pancreatic ductal adenocarcinoma (PDAC)
Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam, The Netherlands,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 33, 2022, Nr. Suppl. 8, S. S1411DOI (Open Access) -
Superiority of [68Ga]Ga-FAPI-46 over [18F]F-FDG PET/CT for cholangiocarcinoma imaging
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S192 – S193DOI (Open Access) -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 49, 2022, Nr. Supplement 1, S. S119 – S120DOI (Open Access) -
A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment. Basel: Karger, Jg. 44, 2021, Nr. Supplement 2, S. 11 – 12DOI (Open Access) -
Ga-68-FAPI for sarcoma imaging : Data from the FAPI-PET prospective observational trial
2021 SNMMI Annual Meeting, June 11th to June 15th, 2021, virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 62, 2021, Nr. Suppl. 1, 126 -
Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumors
Annual Congress of the European Association of Nuclear Medicine, October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 48, 2021, Nr. Suppl. 1, S. S290DOI (Open Access) -
RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer : Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316)
2021 ASCO Annual Meeting, June 4-8, 2021, virtual,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, 3566DOI (Open Access) -
Comprehensive genomic analysis of rare cancers : Results of the MASTER precision oncology trial of the German Cancer Consortium
AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, USA,In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 80, 2020, Nr. Suppl. 16, 821DOI (Open Access) -
Growth factor independence 1 expression induced metabolic vulnerabilities and presents novel therapeutic opportunities in acute myeloid leukemia
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment. Basel: Karger, Jg. 43, 2020, Nr. Suppl. 4, S. 43 – 44DOI (Open Access) -
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients : The RAMTAS trial of the German AIO (KRK-0316)
2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, TPS3617DOI (Open Access) -
PET-directed combined modality therapy for gastroesophageal junction cancer : First results of the prospective MEMORI trial
2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 37, 2019, Nr. 15, 4018DOI (Open Access) -
Metabolic heterogeneity as a PET-biomarker predicts overall survival of pancreatic cancer patients
Annual Congress of the European Association of Nuclear Medicine, EANM'18, October, 13 – 17, 2018, Düsseldorf, Germany,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 45, 2018, Nr. Suppl. 1, S. 97 -
Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy : Interim results of a randomized phase II AIO trial (NEOLAP)
ASCO Gastrointestinal Cancers Symposium 2018, January 18-20, 2018, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. 4_suppl, 348DOI (Open Access) -
Subgroup analysis by baseline (BL) weight-associated parameters : A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g
ASCO Gastrointestinal Cancers Symposium 2018, January 18-20, 2018, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. Suppl. 4, 410DOI (Open Access) -
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1 : A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p
ASCO Gastrointestinal Cancers Symposium 2018, January 18-20, 2018, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. Suppl. 4, 379DOI (Open Access) -
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1 : A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan
ASCO Gastrointestinal Cancers Symposium 2018, January 18-20, 2018, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 36, 2018, Nr. Suppl. 4, 460DOI (Open Access) -
Co-clinical assessment of tumor cellularity in pancreatic cancer
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 1, S. 175 -
Expanded analyses of NAPOLI-1 : Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based the
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 1, S. 170 -
Targeting notch for myeloid reprogramming in pancreatic cancer
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 1, S. 16 -
Resminostat in advanced hepatocellular carcinoma (HCC) : Overall survival subgroup analysis of prognostic factors in the SHELTER trial
2013 ASCO Annual Meeting, 30 May - 3 Jun 2013, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 31, 2013, Nr. 15 Suppl., e15088 -
Redirecting resistance evolution in BRAFV600 melanoma by inhibition of the peroxiredoxin-thioredoxin system2025DOI (Open Access)
-
Mandatory Reporting Measurements in Trials for Potentially Resectable Pancreatic CancerIn: Textbook of Pancreatic Cancer: Principles and Practice of Surgical Oncology / Søreide, Kjetil; Stättner, Stefan (Hrsg.). Cham: Springer Science+Business Media, 2021, S. 107 – 118
-
68Ga-FAPI-46 PET/CT for cancer imaging : Results of a single-center, prospective, interventional, single-arm clinical trial
2025 ASCO Genitourinary Cancers Symposium, February 13-15, 2025, San Francisco, CA, USA,In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 43, 2025, Nr. 5, Supplement, 457 -
68Ga-FAPI PET/CT novel diagnostic tool in sarcoma
Annual Congress of the European Association of Nuclear Medicine, 9-13 September, 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 50, 2023, Nr. 1 supplement, S. S414 – S415 -
DNA damage repair pathways in biliary tract cancer : A new target for precision medicine?
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 34, 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S223DOI (Open Access) -
Analyse zweier prospektiver klinischer Studien der Arbeitsgemeinschaft Internistische Onkologie mit der “Burden of Therapy” (BOTh®TM) Methode : einem neuen Instrument zur Evaluation unerwünschter Ereignisse beim metastasierten Pankreaskarzinom
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment. Basel: Karger, Jg. 45, 2022, Nr. Supplement 2, S. 295DOI (Open Access) -
Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma
ESMO Congress 2021, 16 – 21 September 2021, virtual,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 32, 2021, Nr. Suppl. 5, S. S855DOI (Open Access) -
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy : Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)
ESMO Congress 2021, 16 – 21 September 2021, virtual,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 32, 2021, Nr. Suppl. 5, S. S1091DOI (Open Access) -
Correlation of molecular profiles with response to targeted drugs in pancreatic cancer models
32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 24-25 October 2020, Virtual Conference,In: European Journal of Cancer (EJC). Amsterdam: Elsevier, Jg. 138, 2020, Nr. Supplement 2, S. S58 – S59 -
Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer : The RAMTAS trial of the German AIO
ESMO Virtual Congress 2020, 19 – 21 September / 16 – 18 October 2020,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Suppl. 4, S. S427 – S428DOI (Open Access) -
Anti-leukemic activity through CDK9 inhibition in T-cell prolymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 42, 2019, Nr. Supplement 4: Abstracts, S. 218DOI (Open Access) -
Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies : Results from the MASTER trial of the German Cancer Consortium
AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, USA,In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 79, 2019, Nr. 13, Suppl., 468DOI (Open Access) -
Advanced organoid culture technology in pancreatic cancer and its translational applications
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 1, S. 206DOI (Open Access) -
CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT-PMO-1601)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 1, S. 156DOI (Open Access) -
Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
ESMO 20th World Congress on Gastrointestinal Cancer, 20–23 June 2018, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 29, 2018, Nr. Suppl. 5, S. v42 – v43DOI (Open Access) -
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) : Survival analysis from NAPOLI-1
43rd ESMO Congress (ESMO 2018), 19–23 October 2018, Munich, Germany,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 29, 2018, Nr. Suppl. 8, S. viii250 – viii251DOI (Open Access) -
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
43rd ESMO Congress (ESMO 2018), 19–23 October 2018, Munich, Germany,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 29, 2018, Nr. Suppl. 8, S. viii249 – viii250DOI (Open Access) -
Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer
AACR Annual Meeting 2018, April 14-18, 2018, Chicago, Ill., USA,In: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 78, 2018, Nr. Suppl. 13, 4093DOI (Open Access) -
Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer
30th EORTC – NCI – AACR Symposium; 13 Nov - 16 Nov 2018; Dublin, Ireland,In: European Journal of Cancer (EJC). Amsterdam: Elsevier, Jg. 103, 2018, Nr. Supplement 1, S. e101 -
Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)
ESMO 20th World Congress on Gastrointestinal Cancer, 20–23 June 2018, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 29, 2018, Nr. Suppl. 5, S. v41 – v42DOI (Open Access) -
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial
ESMO 20th World Congress on Gastrointestinal Cancer, 20–23 June 2018, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 29, 2018, Nr. Suppl. 5, S. v42DOI (Open Access) -
The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
ESMO 20th World Congress on Gastrointestinal Cancer, 20–23 June 2018, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 29, 2018, Nr. Suppl. 5, S. v42DOI (Open Access) -
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
43rd ESMO Congress (ESMO 2018), 19–23 October 2018, Munich, Germany,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 29, 2018, Nr. Suppl. 8, S. viii255 – viii256DOI (Open Access) -
CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
42nd ESMO Congress (ESMO 2017), 8-12 September 2017, Madrid, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 28, 2017, Nr. Suppl. 5, S. v538 -
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone
42nd ESMO Congress (ESMO 2017), 8-12 September 2017, Madrid, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 28, 2017, Nr. Suppl. 5, S. v253 -
Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1 : a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 14.–18. Oktober 2016, Leipzig, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 3, S. 259 -
Final results of NAPOLI-1 : A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 27, 2016, Nr. Suppl. 6, S. vi211 -
Gemcitabine impairs tumor perfusion in stroma rich murine endogenous PDAC
28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 29 to December 2, 2016, Munich, Germany,In: European Journal of Cancer (EJC). Amsterdam: Elsevier, Jg. 69, 2016, Nr. Suppl. 1, S. S67 – S68 -
Identification of metabolic changes in Pancreatic Ductal Adenocarcinoma
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ, 32. Deutscher Krebskongress, 24.-27. Februar 2016, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 1, S. 76 – 77 -
Patient-derived organoids to model intra- and intertumoral heterogeneity of pancreatic cancer in high-throughput drug screens
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 1, S. 162 -
Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 14.–18. Oktober 2016, Leipzig, Germany,In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 3, S. 260 -
RAC1 activity is necessary for the development of murine undifferentiated PDAC
28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 29 to December 2, 2016, Munich, Germany,In: European Journal of Cancer (EJC). Amsterdam: Elsevier, Jg. 69, 2016, Nr. Suppl. 1, S. 140 -
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1 : A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 27, 2016, Nr. Suppl. 6, S. vi234 -
Use of Diffusion-weighted magnetic resonance imaging for therapy response evaluation in pancreatic cancer
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment. Basel: Karger, Jg. 39, 2016, Nr. Suppl. 1, S. 113 – 114 -
Na-Folfiri plus sunitinib versus Na-Folfiri alone in advanced chemorefractory esophagogastric cancer patients : A randomized double-blinded placebo-controlled multicentric AIO phase II trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie. Basel: Karger, Jg. 36, 2013, Nr. Suppl. 7, S. 74 -
Clinical update on the phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC) - The Shelter Study
13th World Congress on Gastrointestinal Cancer 22–25 June 2011, Barcelona, Spain,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 22, 2011, Nr. Suppl. 5, S. v76 – v76